H.C. Wainwright has recently initiated Beam Therapeutics Inc (BEAM) stock to Buy rating, as announced on July 23, 2024, according to Finviz. Earlier, on January 29, 2024, JP Morgan had raised the stock from a Neutral to Overweight, setting a price target of $40 for BEAM stock. BofA Securities also reduced Neutral rating with a price target of $35. Additionally, Jefferies reduced Hold rating on December 8, 2023, with a target price of $30. Leerink Partners analysts, in their report published on October 20, 2023, also reduced Market Perform rating and set a price target of $75 for Beam Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Beam Therapeutics Inc (BEAM) Stock Trading Recap
On Tuesday, Beam Therapeutics Inc (BEAM) stock saw a decline, ending the day at $23.41 which represents a decrease of $-1.09 or -4.45% from the prior close of $24.5. The stock opened at $24.4 and touched a low of $23.12 during the day, reaching a high of $24.4. The volume of shares traded was 0.91 million falling short of the average volume of 0.98 million.
BEAM Stock Performance and Moving Averages
In recent trading, Beam Therapeutics Inc (BEAM) stock price has shown some volatility, fluctuating -5.49% over the last five trades and -12.26% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -23.37%, and it has gained 3.72% in the previous three months. Currently, BEAM is trading at -5.40%, -10.35%, and -14.02% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, BEAM, a Healthcare sector stock, is trading -52.71% below its 52-week high but remains 38.11% above its 52-week low. The Average True Range (ATR) (14 days) of 1.28 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Beam Therapeutics Inc’s Profitability and Valuation Ratios
Beam Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -52.31% and a profit margin of -40.56%, with a gross margin of -23.37%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Beam Therapeutics Inc’s market capitalization stands at $1.93 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 5.47, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 2.26, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 13.13% of Beam Therapeutics Inc (BEAM)’s shares, while financial institutions hold 81.31%.
Notable insider trades include Evans John M., CEO at Beam Therapeutics Inc (BEAM), who sold 60000 shares on Jun 27 ’24, at $24.5 each, totaling $1.47 million. On Apr 02 ’24, Simon Amy, Chief Medical Officer, sold 16530 shares for $30.54 each, amounting to $0.50 million. Additionally, on Apr 01 ’24, Simon Amy sold 7157 shares at $32.13 each, generating $0.23 million.
